Non-DMa
|
DMa
|
---|
HbA1C/TyG†
|
HR (95%CI)
|
P value
|
HR (95%CI)
|
P value
|
---|
Low/low (referent)
|
–
|
< 0.001
|
–
|
–
|
Low/High
|
1.91 (1.14–3.20)
|
0.014
|
2.10 (1.41–3.12)
|
< 0.001
|
High/Low
|
1.54 (0.90–2.62)
|
0.116
|
1.88 (1.26–2.81)
|
0.002
|
High/High
|
3.22 (2.02–5.16)
|
< 0.001
|
2.79(1.98–3.93)
|
< 0.001
|
FPG/TyG†
|
HR (95%CI)
|
P value
|
HR (95%CI)
|
P value
|
Low/low (referent)
|
–
|
< 0.001
|
–
|
–
|
Low/High
|
1.73 (1.23–2.45)
|
0.002
|
1.62 (1.01–2.62)
|
0.047
|
High/Low
|
0.40 (0.06–2.93)
|
0.369
|
1.4 3 (0.87–2.34)
|
0.161
|
High/High
|
3.56 (1.65–7.66)
|
0.001
|
1.99 (1.36–2.91)
|
< 0.001
|
- FPG fasting plasma glucose, HbA1C Glycosylated haemoglobin, TyG triglyceride glucose, HR hazard ratio, CI confidence interval
- †Different cutoff values were used by diabetes status. In non-DM group: Median HbA1C: 5.8%, median FBG: 5.52 mmol/L, median TyG: 8.74; In DM Group: guideling-guide HbA1C: 7.0%, equivalent percentage FPG: 7.11 mmol/L, equivalent percentage TyG:8.95
- aThe log-rank test and backward stepwise selection methods in a Cox proportional hazards regression model was performed; adjusted for age, sex, BMI, current smoker, hypertension, previous MI, previous stroke, previous PCI, previous CABG, non-HDL-C, lipid-lowering and antidiabetes medication use